231 related articles for article (PubMed ID: 33161724)
1. Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China.
Yang Y; Yang N; Wu L; Ouyang Q; Fang J; Li J; Liao W; Cai K; Huang J; Li J; Zhang Y; Wang X; Zhang H; Xu N; Zhao Q; Hu X; Li W; Zhong W; Zhong D; Cheng G; Ye S; Zhong M; Wang D; Liu H; Zheng J; Liu X; Xu H; Zhang L
Chin Clin Oncol; 2020 Oct; 9(5):68. PubMed ID: 33161724
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
[TBL] [Abstract][Full Text] [Related]
3. Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Kim HJ; Shin SW; Song EK; Lee NR; Kim JS; Ahn JS; Yun HJ; Cho YH; Park KU; Kim SY; Jang JS; Kim SW; Lee HW; Lee SR; Kim YS; Lee SN; Ko YH; Kim HJ; Kang JH
Oncologist; 2015 Dec; 20(12):1440-7. PubMed ID: 26512046
[TBL] [Abstract][Full Text] [Related]
4. Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Zelek L; Navari R; Aapro M; Scotté F
Cancer Med; 2023 Aug; 12(15):15769-15776. PubMed ID: 37537943
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
Botteman M; Nickel K; Corman S; Turini M; Binder G
Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy.
Ioroi T; Furukawa J; Kume M; Hirata S; Utsubo Y; Mizuta N; Miyake H; Fujisawa M; Hirai M
Support Care Cancer; 2018 May; 26(5):1419-1423. PubMed ID: 29147855
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
8. Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting.
Kang JH; Kwon JH; Lee YG; Park KU; An HJ; Sohn J; Seol YM; Lee H; Yun HJ; Ahn JS; Yang JH; Song H; Koo DH; Kim JY; Kim GM; Kim HJ
Cancer Res Treat; 2020 Jul; 52(3):907-916. PubMed ID: 32192275
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
11. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
Rapoport BL
Curr Med Res Opin; 2014 Sep; 30(9):1875-81. PubMed ID: 24911369
[TBL] [Abstract][Full Text] [Related]
13. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
[TBL] [Abstract][Full Text] [Related]
15. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
[TBL] [Abstract][Full Text] [Related]
16. Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Patel MP; Woodring S; Randazzo DM; Friedman HS; Desjardins A; Healy P; Herndon JE; McSherry F; Lipp ES; Miller E; Peters KB; Affronti ML
Support Care Cancer; 2020 May; 28(5):2229-2238. PubMed ID: 31440823
[TBL] [Abstract][Full Text] [Related]
17. Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Inoue T; Kimura M; Uchida J; Nishino K; Kumagai T; Taniguchi J; Imamura F
Int J Clin Oncol; 2017 Jun; 22(3):600-604. PubMed ID: 28144884
[TBL] [Abstract][Full Text] [Related]
18. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
[TBL] [Abstract][Full Text] [Related]
20. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.
Kang HJ; Loftus S; Taylor A; DiCristina C; Green S; Zwaan CM
Lancet Oncol; 2015 Apr; 16(4):385-94. PubMed ID: 25770814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]